The NEO-1 gene may serve as a potential biomarker for predicting acute myocardial infarction

Objectives This study elucidated the association between acute myocardial infarction (AMI) and Neogenin-1 (NEO-1) using proteomics to identify NEO-1 as a promising circulating biomarker for AMI risk prediction. Methods A total of 107 participants were included in the analysis, comprising 45 control subjects without coronary heart disease (non-coronary heart disease [NCHD]; as a control group) and 62 patients with AMI. Furthermore, mRNA levels were elucidated via RT-qPCR, whereas the protein content was measured using enzyme-linked immunosorbent assay (ELISA). Lastly, the acquired data were elucidated and compared. Results The data showed that relative to the NCHD group, the AMI group’s NEO-1 mRNA level in peripheral blood (PB) mononuclear cells was 1.47 times higher (p<0.05), whereas NEO-1 protein levels were 1.50 times higher (p<0.05). Furthermore, in AMI patients, the expression of NEO-1 was not related to smoking, total cholesterol, alcohol consumption, triglycerides, age, high-density lipoprotein cholesterol, hypertension, or platelets. Moreover, Logistic regression assessment revealed that AMI was associated with elevated NEO-1 expression and enhanced fasting blood glucose. Conclusions This study revealed that relative to the NCHD patients, AMI patients had elevated PB NEO-1 expression, which was an independent risk factor for AMI. These findings indicate that NEO-1 expression is a potential bio-index for AMI.